Related Experiment Video
Updated: Mar 21, 2026
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint
Shaohua Xu1, Zhen Tao2, Bo Hai3
1Department of Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai 201204, China.
Abstract:
Immune checkpoint blockade of the inhibitory immune receptors PD-L1, PD-1 and CTLA-4 has emerged as a successful treatment strategy for several advanced cancers. Here we demonstrate that miR-424(322) regulates the PD-L1/PD-1 and CD80/CTLA-4 pathways in chemoresistant ovarian cancer. miR-424(322) is inversely correlated with PD-L1, PD-1, CD80 and CTLA-4 expression. High levels of miR-424(322) in the tumours are positively correlated with the progression-free survival of ovarian cancer patients. Mechanistic investigations demonstrated that miR-424(322) inhibited PD-L1 and CD80 expression through direct binding to the 3'-untranslated region. Restoration of miR-424(322) expression reverses chemoresistance, which is accompanied by blockage of the PD-L1 immune checkpoint. The synergistic effect of chemotherapy and immunotherapy is associated with the proliferation of functional cytotoxic CD8+ T cells and the inhibition of myeloid-derived suppressive cells and regulatory T cells. Collectively, our data suggest a biological and functional interaction between PD-L1 and chemoresistance through the microRNA regulatory cascade.
Insights
MicroRNA-424(322) targets immune checkpoints like PD-L1 and CTLA-4 in ovarian cancer. Restoring this microRNA can reverse chemoresistance and improve patient survival by enhancing anti-tumor immunity.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Immune checkpoint inhibitors targeting PD-L1, PD-1, and CTLA-4 are effective in advanced cancers.
- Ovarian cancer often develops chemoresistance, necessitating novel therapeutic strategies.
- MicroRNAs play crucial roles in regulating gene expression and cellular processes.
Purpose of the Study:
- To investigate the role of miR-424(322) in regulating immune checkpoints in chemoresistant ovarian cancer.
- To explore the correlation between miR-424(322) levels and patient outcomes.
- To elucidate the mechanism by which miR-424(322) affects chemoresistance and immune responses.
Main Methods:
- Correlation analysis of miR-424(322) expression with PD-L1, PD-1, CD80, and CTLA-4.
- Mechanistic studies involving direct binding of miR-424(322) to 3'-untranslated regions.
- Assessment of chemoresistance reversal and immune cell populations upon miR-424(322) restoration.
Main Results:
- miR-424(322) expression is inversely correlated with PD-L1, PD-1, CD80, and CTLA-4.
- High miR-424(322) levels correlate with improved progression-free survival in ovarian cancer patients.
- Restoration of miR-424(322) reversed chemoresistance, blocked PD-L1, and promoted cytotoxic CD8+ T cells while inhibiting suppressive immune cells.
Conclusions:
- miR-424(322) acts as a key regulator of the PD-L1/PD-1 and CD80/CTLA-4 pathways in chemoresistant ovarian cancer.
- miR-424(322) has potential as a therapeutic target to overcome chemoresistance and enhance immunotherapy efficacy.
- A novel link between microRNA regulation, immune checkpoints, and chemoresistance in ovarian cancer is established.
More Related Videos
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...